ArticleFrontiers in microbiology2025
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Leveraging artificial intelligence for analysis of the gut microbiome for dementia diagnosis: a scoping review and discussion.Frontiers in dementia · 2026Pooled it
- Microbiota-gut-brain axis imbalance: a promising therapeutic target for preserving brain health in high-altitude environment.Frontiers in neuroscience · 2026Review
- Probiotics as a Complementary Medicine in Neurologic Disorders.Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: High-altitude environments have significant effects on brain function, particularly a decline in cognitive function, due to insufficient oxygen supply. The microbiome-gut-brain axis (MGBA) plays an important role in regulating cognitive function, but its specific mechanism of action in high-altitude environments is unclear. Therefore, the aim of this study was to investigate whether the probiotic Methods and results: Sixty C57BL/6 mice aged 8 weeks were randomly divided into four groups: control, high altitude exposure (HA), HL79-treated (P), and high altitude exposure plus HL79-treated (HAP). the HA and HAP groups were exposed to a low-pressure oxygen chamber at a simulated altitude of 3,500-4,000 m for 20 weeks, while the Control and P groups were maintained at the normal barometric pressure level. Probiotic HL79 was given daily by gavage in the P and HAP groups, while saline gavage was given daily in the other two groups. The cognitive functions of the mice were assessed by new object recognition test and elevated plus maze test. The results showed that HL79 treatment significantly improved the working memory abilities of high altitude exposed mice. In addition, HL79 treatment improved antioxidant capacity, decreased malondialdehyde (MDA) content, and increased superoxide dismutase (SOD) and catalase (CAT) activities in serum and whole brain tissue. Gut microbiota analysis showed that HL79 was able to modulate the structure of gut microbiota and increase the relative abundance of beneficial flora in high altitude environment. Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.